Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substance for improving lethality of immune cells as well as preparation and application of substance

A technology of immune cells and lethality, applied in the field of medicine, can solve problems such as deficiency

Pending Publication Date: 2021-04-09
HANDAN PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in previous studies, the research on the core active ingredients in Moluotan that can improve the immune function of atrophic gastritis and immune regulatory factors is relatively lacking.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substance for improving lethality of immune cells as well as preparation and application of substance
  • Substance for improving lethality of immune cells as well as preparation and application of substance
  • Substance for improving lethality of immune cells as well as preparation and application of substance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Molodan Substances for the Treatment of Atrophic Gastritis with Immunocompromise

[0039] Chronic atrophic gastritis is usually accompanied by hypoimmunity, which is closely related to signaling pathways such as immune metabolism, apoptosis, proliferation, and DNA damage repair. The present invention establishes morodan fingerprints through metabolomics analysis. Further combined with literature information mining, the candidate active ingredients in moluotan were preliminarily screened out. Afterwards, through cytological and molecular experiments, the effective medicinal ingredients in Moluotan for the treatment of atrophic gastritis with low immune function were identified. The steps are as follows:

[0040] 1. Morodan fingerprint establishment

[0041] In order to identify and identify the components in Morodan that are effective in treating atrophic gastritis with low immune function, the inventors conducted metabolomics analysis on Moluotan, and successfully ide...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a substance for improving the lethality of immune cells as well as a preparation and application of the substance. The substance for improving the lethality of immune cells comprises one or more of berberine, benzoyloxypaeoniflorin, methylophiopogonone A, canadin(tetrahydroberberine), leucoside(kaempferol 3-O-sambubioside), cheilanthifoline, bucuculline, sibirioside A, harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, 3,5-Dicaffeoyl quinic acid, L-arginine, 3-O-feruloylquinic acid, lucidone, atractyloside A, ginsenoside Rh3, Cholan-24-oic acid, oleuropein, parishin A, parishin B, p-hydroxyphenylethyl trans-ferulate, Palbinone, pseudo-ginsenoside RT1, pimpinellin, 4-hydroxybenzoic acid, Eburicoic acid, alismoxide and alpha-cyperone. According to the substance disclosed by the invention, immunity-related genes such as CD46, MUC16, TGF-beta and the like and GAST and SS18 are selected as direct or indirect regulation and control target genes from genes of which the expression quantity is obviously changed in transcriptome analysis data.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a substance for improving the lethality of immune cells, its preparation and application. Background technique [0002] Chronic atrophic gastritis (CAG) is characterized by atrophy of gastric mucosal epithelium and glandular tissue, reduction in the number of mucosal cells, thinning of gastric mucosa, thickening of the submucosal layer, or accompanied by pyloric gland metaplasia and intestinal gland metaplasia, or abnormal Chronic digestive disease characterized by typical hyperplasia. my country is an area with a high incidence of gastric cancer, and the occurrence of most gastric cancer follows the gastric cancer occurrence model proposed by Correa cascade reaction: normal gastric mucosa - superficial gastritis - atrophic gastritis - small intestine-type intestinal metaplasia - large intestine-type intestinal metaplasia - Dysplasia (moderate to severe) - gastric ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K45/06A61K31/4375A61K31/7048A61K31/352A61K31/4741A61K31/7028A61K31/407A61K31/473A61K31/704A61K31/216A61K31/198A61K31/57A61K31/7032A61K31/575A61K31/7034A61K31/122A61K31/37A61K31/192A61K31/047A61P1/04A61P37/04
CPCA61K45/00A61K45/06A61K31/4375A61K31/7048A61K31/352A61K31/4741A61K31/7028A61K31/407A61K31/473A61K31/704A61K31/216A61K31/198A61K31/57A61K31/7032A61K31/575A61K31/7034A61K31/122A61K31/37A61K31/192A61K31/047A61P1/04A61P37/04
Inventor 陈致慜殷苗苗刘会云王珍王梦蕾
Owner HANDAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products